Vivos Therapeutics, Inc.
VVOS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $7 | $4 | $3 | $4 |
| % Growth | 77.6% | 26.7% | -18.4% | – |
| Cost of Goods Sold | $3 | $2 | $2 | $2 |
| Gross Profit | $4 | $2 | $2 | $2 |
| % Margin | 58% | 55.2% | 50% | 56.7% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $8 | $6 | $5 | $4 |
| SG&A Expenses | $8 | $7 | $5 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $8 | $7 | $5 | $5 |
| Operating Income | -$4 | -$5 | -$4 | -$3 |
| % Margin | -64.1% | -127.4% | -124% | -75.9% |
| Other Income/Exp. Net | -$1 | -$0 | $0 | -$0 |
| Pre-Tax Income | -$5 | -$5 | -$4 | -$3 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$5 | -$5 | -$4 | -$3 |
| % Margin | -79.6% | -131.2% | -128.1% | -76.4% |
| EPS | -0.49 | -0.55 | -0.45 | -0.48 |
| % Growth | 10.9% | -22.2% | 6.2% | – |
| EPS Diluted | -0.49 | -0.55 | -0.45 | -0.48 |
| Weighted Avg Shares Out | 11 | 9 | 9 | 6 |
| Weighted Avg Shares Out Dil | 11 | 9 | 9 | 6 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$5 | -$5 | -$4 | -$3 |
| % Margin | -73.9% | -123.2% | -118.2% | -72.6% |